Видео ютуба по тегу Refractory Cll

Ian W Flinn, ASCO 2018 – Recent advances in relapsed/refractory CLL, DLBCL & follicular lymphoma
Ian W Flinn, ASCO 2018 – Recent advances in relapsed/refractory CLL, DLBCL & follicular lymphoma
December 6, 2022 CLLAN Webinar: CLL treatment in the relapsed-refractory setting
December 6, 2022 CLLAN Webinar: CLL treatment in the relapsed-refractory setting
Acalabrutinib for Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma - Dr. Richard Furman
Acalabrutinib for Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma - Dr. Richard Furman
Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL
Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL
Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib
Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib
Options for Managing Refractory CLL
Options for Managing Refractory CLL
Dr. Ghia on Updated ASCEND Trial Results in Relapsed/Refractory CLL
Dr. Ghia on Updated ASCEND Trial Results in Relapsed/Refractory CLL
Liso-Cel in CLL
Liso-Cel in CLL
ASH Highlights: Combination Oral Therapy for Relapsed CLL Shows Promise
ASH Highlights: Combination Oral Therapy for Relapsed CLL Shows Promise
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
Venetoclax Plus Rituximab in Relapsed/Refractory CLL
Venetoclax Plus Rituximab in Relapsed/Refractory CLL
Addressing Challenges for Patients With Relapsed CLL
Addressing Challenges for Patients With Relapsed CLL
Relapsed and Refractory CLL/SLL
Relapsed and Refractory CLL/SLL
Thursday Webinar - Management of relapsed/refractory Acute Lymphoblastic Leukaemia in Adult
Thursday Webinar - Management of relapsed/refractory Acute Lymphoblastic Leukaemia in Adult
Novel Approaches to Treating Relapsed/Refractory CLL
Novel Approaches to Treating Relapsed/Refractory CLL
MURANO study: exciting times in CLL
MURANO study: exciting times in CLL
Case 4: Treatment of Relapsed CLL
Case 4: Treatment of Relapsed CLL